Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Cash & Equivalents: 2014-2025

Historic Cash & Equivalents for vTv Therapeutics (VTVT) over the last 12 years, with Sep 2025 value amounting to $98.5 million.

  • vTv Therapeutics' Cash & Equivalents rose 136.79% to $98.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.5 million, marking a year-over-year increase of 136.79%. This contributed to the annual value of $36.7 million for FY2024, which is 289.01% up from last year.
  • As of Q3 2025, vTv Therapeutics' Cash & Equivalents stood at $98.5 million, which was up 280.00% from $25.9 million recorded in Q2 2025.
  • vTv Therapeutics' 5-year Cash & Equivalents high stood at $98.5 million for Q3 2025, and its period low was $8.2 million during Q3 2023.
  • Moreover, its 3-year median value for Cash & Equivalents was $31.1 million (2025), whereas its average is $34.6 million.
  • In the last 5 years, vTv Therapeutics' Cash & Equivalents soared by 972.80% in 2021 and then slumped by 46.29% in 2023.
  • vTv Therapeutics' Cash & Equivalents (Quarterly) stood at $13.4 million in 2021, then dropped by 9.61% to $12.1 million in 2022, then fell by 22.10% to $9.4 million in 2023, then surged by 289.01% to $36.7 million in 2024, then skyrocketed by 136.79% to $98.5 million in 2025.
  • Its last three reported values are $98.5 million in Q3 2025, $25.9 million for Q2 2025, and $31.1 million during Q1 2025.